Company Aurinia Pharmaceuticals Inc. Toronto S.E.
Equities
CA05156V1022
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Drugs
100.0
%
| 134 | 100.0 % | 176 | 100.0 % | +30.95% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
90.0
%
| 102 | 76.4 % | 158 | 90.0 % | +54.17% |
Japan
10.0
%
| 31 | 23.5 % | 18 | 10.0 % | -44.24% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 15/06/93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
Robert Foster
FOU | Founder | 65 | 15/06/93 |
Joseph Miller
DFI | Director of Finance/CFO | 50 | 26/04/20 |
Compliance Officer | 42 | 31/12/13 | |
Matthew Donley
COO | Chief Operating Officer | 55 | 17/07/19 |
Sue Evans
LAW | General Counsel | - | 31/12/13 |
Fran Lynch
SAM | Sales & Marketing | - | 24/02/20 |
Scott Habig
PRN | Corporate Officer/Principal | 64 | 14/07/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 15/06/93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 25/06/19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
Jill Leversage
BRD | Director/Board Member | 67 | 12/11/19 |
Jeffrey Bailey
BRD | Director/Board Member | 62 | 17/08/23 |
Michael Martin
FOU | Founder | 52 | 15/06/93 |
Karen Smith
BRD | Director/Board Member | 56 | 17/08/23 |
David Jaynee
BRD | Director/Board Member | 67 | 25/05/15 |
Director/Board Member | 44 | 13/06/21 | |
Daniel Billen
CHM | Chairman | 70 | 28/04/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 143,019,365 | 132,907,345 ( 92.93 %) | 0 | 92.93 % |
Company contact information
Aurinia Pharmaceuticals, Inc.
14315 – 118 Avenue Suite 140
T5L 4S6, Edmonton
+250 744 2487
http://www.auriniapharma.comSector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |